CREB

CREB CREB is a cellular transcription factor that binds DNA at cAMP response elements to regulate gene expression in response to diverse signals. It integrates inputs from signaling cascades driven by neurotransmitters, hormones, and growth factors to modulate transcriptional programs that influence development, plasticity, metabolism, and survival. CREB activity is studied across molecular biology, neuroscience, endocrinology, and cancer research and is implicated in processes investigated by many laboratories and consortia worldwide.

Structure and biochemical properties

CREB belongs to the basic leucine zipper (bZIP) family alongside proteins such as ATF-1, ATF-2, c-Fos, c-Jun, and CREM. The protein contains an N-terminal glutamine-rich transcriptional activation domain and a C-terminal bZIP domain mediating DNA binding and dimerization, a topology comparable to that of GABP-alpha and USF1. CREB harbors multiple phosphorylation sites including Ser133, a key residue modified by kinases including Protein kinase A, CaMKIV, and MSK1, paralleling regulatory motifs found in p53 and NF-κB family members. Structural studies using techniques pioneered by groups such as those at Max Planck Institute and Cold Spring Harbor Laboratory show that CREB binds the palindromic 8‑bp cAMP response element (CRE) as a homo- or heterodimer, forming contacts with the DNA major groove similar to interactions seen in the bZIP structural paradigm. CREB interacts with coactivators that possess KIX domains like CBP and p300, and these interactions are stabilized by post-translational modifications such as phosphorylation and acetylation analogous to regulation of HIF-1α and Myc.

Activation and regulation

Activation of CREB occurs through phosphorylation by signaling pathways initiated at receptors exemplified by β-adrenergic receptor, NMDA receptor, TrkB, and insulin receptor; second messenger systems involving cAMP and Ca2+ mobilization converge on kinases such as PKA, CaMKII, ERK1/2 via RSK, and MSK1. The phospho-Ser133 mark recruits the KIX domain of coactivators CBP and p300, analogous to recruitment events documented for CREM and c-Myb. Negative regulation occurs through phosphatases including PP1 and PP2A, interaction with repressor proteins such as ICER, and ubiquitin-dependent turnover mediated by E3 ligases similar to those regulating p27Kip1 and Cyclin D1. Crosstalk with pathways governed by PI3K-Akt, MAPK, and GSK3β adjusts CREB output in contexts studied in labs at institutions like Harvard Medical School and Johns Hopkins University.

Target genes and transcriptional mechanisms

CREB controls transcription of genes involved in neuronal function, metabolism, and cell survival by binding CRE motifs in promoters and enhancers of targets including immediate early genes like c-Fos, neurotrophins like BDNF, metabolic regulators such as PEPCK and GLUT4, and anti-apoptotic factors like BCL-2. Genome-wide chromatin immunoprecipitation studies performed by consortia including ENCODE and groups at Broad Institute reveal CREB occupancy at promoters and distal enhancers that often coincide with histone acetylation deposited by CBP/p300 and chromatin remodelers such as SWI/SNF. CREB-dependent transcription involves assembly of the preinitiation complex featuring TFIID, mediator subunits studied at EMBL, and elongation factors including P-TEFb, producing regulated transcriptional elongation similar to mechanisms controlling HIV-1 proviral gene expression. Alternative promoter usage and cooperation with other transcription factors like CREM, AP-1, and NFAT diversify CREB target repertoires observed in transcriptomic datasets from groups at Salk Institute and MIT.

Physiological roles and functions

In the nervous system, CREB is central to long-term synaptic plasticity, memory consolidation, and neuronal survival, phenomena investigated in systems ranging from Aplysia californica studies by labs of Eric Kandel to mammalian work at Cold Spring Harbor Laboratory and Stanford University. In endocrine contexts CREB mediates hormone-responsive gene programs downstream of glucagon and adrenaline, regulating gluconeogenesis and energy homeostasis in liver and muscle, processes researched at NIH and Max Planck Institute for Molecular Physiology. CREB contributes to cardiac hypertrophy and stress responses linked to signaling via β-adrenergic receptor and MAPK cascades, and it influences immune cell differentiation and cytokine expression in studies from institutions such as University of Oxford and Pasteur Institute. During development CREB orchestrates cell survival and differentiation in neuronal lineages and pancreatic beta‑cells, aligning with developmental paradigms explored at Wellcome Trust Sanger Institute and Karolinska Institutet.

Involvement in disease and therapeutic potential

Aberrant CREB activity is implicated in neuropsychiatric disorders including depression and addiction, neurodegenerative diseases such as Alzheimer's disease studied at Mayo Clinic and UCL, metabolic disorders like type 2 diabetes examined at Imperial College London, and oncogenesis in cancers including acute myeloid leukemia and certain solid tumors reported by research groups at MD Anderson Cancer Center and Dana-Farber Cancer Institute. Therapeutic strategies target upstream kinases (e.g., PKA inhibitors), disrupt CREB–CBP interactions with small molecules modeled after structural studies at University of California, San Francisco, or modulate downstream effectors such as BDNF or BCL-2 pathways in clinical programs run by organizations like National Institute of Mental Health and pharmaceutical companies including Pfizer and Roche. Biomarker development and gene therapy approaches leveraging CREB-regulated promoters are under investigation in academic-industry collaborations at Genentech and academic centers worldwide.

Category:Transcription factors